Difference between revisions of "Oprelvekin (Neumega)"
Jump to navigation
Jump to search
(Created page with "=Mechanism of action= Synthetic version of IL-11, a thrombopoietic growth factor that directly stimulates the proliferation of hematopoietic stem cells and megakaryocyte proge...") |
Warner-admin (talk | contribs) m (Text replacement - "Category:Drug index" to "Category:Drugs") |
||
Line 6: | Line 6: | ||
*9/18/2002: Label "indicated for the prevention of severe thrombocytopenia and the reduction of the need for platelet transfusions following myelosuppressive chemotherapy in adult patients with nonmyeloid malignancies who are at high risk of severe thrombocytopenia." | *9/18/2002: Label "indicated for the prevention of severe thrombocytopenia and the reduction of the need for platelet transfusions following myelosuppressive chemotherapy in adult patients with nonmyeloid malignancies who are at high risk of severe thrombocytopenia." | ||
− | [[Category: | + | [[Category:Drugs]] |
[[Category:Hematopoietic growth factors]] | [[Category:Hematopoietic growth factors]] | ||
[[Category:Megakaryocyte growth factors]] | [[Category:Megakaryocyte growth factors]] | ||
[[Category:Drugs FDA approved in 1997]] | [[Category:Drugs FDA approved in 1997]] |
Revision as of 22:29, 13 June 2018
Mechanism of action
Synthetic version of IL-11, a thrombopoietic growth factor that directly stimulates the proliferation of hematopoietic stem cells and megakaryocyte progenitor cells and induces megakaryocyte maturation resulting in increased platelet production.
History of changes in FDA indication
- 11/25/1997: Initial FDA approval (no label available on Drugs @ FDA)
- 9/18/2002: Label "indicated for the prevention of severe thrombocytopenia and the reduction of the need for platelet transfusions following myelosuppressive chemotherapy in adult patients with nonmyeloid malignancies who are at high risk of severe thrombocytopenia."